NO20073175L - Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet - Google Patents

Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet

Info

Publication number
NO20073175L
NO20073175L NO20073175A NO20073175A NO20073175L NO 20073175 L NO20073175 L NO 20073175L NO 20073175 A NO20073175 A NO 20073175A NO 20073175 A NO20073175 A NO 20073175A NO 20073175 L NO20073175 L NO 20073175L
Authority
NO
Norway
Prior art keywords
interleukin
medical field
antigenic epitopes
related antibodies
antibodies
Prior art date
Application number
NO20073175A
Other languages
English (en)
Norwegian (no)
Inventor
Giovanni Monteleone
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Publication of NO20073175L publication Critical patent/NO20073175L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20073175A 2004-11-29 2007-06-22 Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet NO20073175L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000586A ITRM20040586A1 (it) 2004-11-29 2004-11-29 Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
PCT/IT2005/000691 WO2006057027A1 (fr) 2004-11-29 2005-11-24 Epitopes antigeniques de l'interleukine-21, anticorps correspondants et leur utilisation dans le domaine medical

Publications (1)

Publication Number Publication Date
NO20073175L true NO20073175L (no) 2007-08-23

Family

ID=36013301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073175A NO20073175L (no) 2004-11-29 2007-06-22 Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet

Country Status (14)

Country Link
US (1) US20090214549A1 (fr)
EP (1) EP1817327A1 (fr)
JP (1) JP2008521797A (fr)
KR (1) KR20070084407A (fr)
CN (1) CN101137664A (fr)
AU (1) AU2005308411A1 (fr)
BR (1) BRPI0516661A (fr)
CA (1) CA2587889A1 (fr)
EA (1) EA200701092A1 (fr)
IL (1) IL183251A0 (fr)
IT (1) ITRM20040586A1 (fr)
MX (1) MX2007006355A (fr)
NO (1) NO20073175L (fr)
WO (1) WO2006057027A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567973B1 (fr) * 2005-11-28 2014-05-14 Zymogenetics, Inc. Antagonistes IL-21
EP1960433A2 (fr) 2005-11-28 2008-08-27 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009047360A1 (fr) * 2007-10-11 2009-04-16 Novo Nordisk A/S Anticorps il-21
DK2217268T3 (en) 2007-12-07 2016-08-15 Zymogenetics Inc MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
WO2009132821A1 (fr) * 2008-04-28 2009-11-05 Giuliani International Limited Protéines de liaison à l’interleukine (il-21) et procédés de préparation et d’utilisation de celles-ci
CN103443124A (zh) * 2011-01-17 2013-12-11 诺沃—诺迪斯克有限公司 Il-21配体
EP2714198A1 (fr) * 2011-05-31 2014-04-09 Novo Nordisk A/S Epitopes de il-21 et ligands de il-21
AU2014302028B2 (en) 2013-06-27 2019-09-19 Monash University IL-21 binding proteins and uses thereof
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
CA2948275C (fr) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Molecules de liaison specifiques de l'il-21 et leurs utilisations
EP3233914A1 (fr) 2014-12-19 2017-10-25 Mabtech Ab Composition, kit et procédé servant à l'inhibition de l'activation médiée par il-21 de cellules humaines
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061617A1 (fr) * 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukine 21 et 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6929932B2 (en) * 2001-11-05 2005-08-16 Zymogenetics, Inc. IL-21 antagonists
AU2003230834A1 (en) * 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
CA2529520A1 (fr) * 2003-06-19 2004-12-29 Centocor, Inc. Analogues de l'interleukine-21

Also Published As

Publication number Publication date
EA200701092A1 (ru) 2008-02-28
US20090214549A1 (en) 2009-08-27
CN101137664A (zh) 2008-03-05
BRPI0516661A (pt) 2008-09-16
KR20070084407A (ko) 2007-08-24
MX2007006355A (es) 2007-07-09
CA2587889A1 (fr) 2006-06-01
WO2006057027A1 (fr) 2006-06-01
ITRM20040586A1 (it) 2005-02-28
IL183251A0 (en) 2007-09-20
EP1817327A1 (fr) 2007-08-15
AU2005308411A1 (en) 2006-06-01
JP2008521797A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
NO20073175L (no) Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
UA116614C2 (uk) Антитіло до фактора d і його застосування
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20083066L (no) Antistoffmolekyler med spesifisitet for human-IL-6
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20092652L (no) Konstruert anti-TSLP-antistoff
AR048599A1 (es) Anticuerpos anti-p-selectina
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
WO2007074193A3 (fr) Procede d'analyse d'expression differentielle dans le cancer colorectal
CL2008001659A1 (es) Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades.
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
EA200701390A1 (ru) Способ получения легкодоступного клеточного материала из пуповинной крови и композиция на его основе
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
DE60320009D1 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
DE602005023840D1 (de) Azabicyclooctan-3-onderivate und deren verwendung
EA201790489A1 (ru) ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
EA200701826A1 (ru) Способ и композиция для лечения диабета
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application